Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032042 | 1.00 | CCR2 (0.40) | CCR2CCR3CCR5PIK3CDPIK3R1 | |
| SCHEMBL15033734 | 0.83 | CCR2 (0.63) | CCR2CCR5 | |
| SCHEMBL10178369 | 0.77 | L3MBTL3 (0.50) | CCR2CCR5PIK3CDKMT2AMEN1 | |
| SCHEMBL15033677 | 0.77 | CCR2 (0.46) | CCR2CCR5PIK3CDPIK3R1POLB | |
| SCHEMBL15032046 | 0.75 | CCR2 (0.61) | CCR2CCR5 | |
| SCHEMBL15032049 | 0.75 | CCR2 (0.61) | CCR2CCR5 | |
| SCHEMBL15033670 | 0.75 | CCR2 (0.46) | CCR2CCR5IRAK4 | |
| SCHEMBL15032057 | 0.74 | CCR2 (0.48) | CCR2CCR5 | |
| SCHEMBL15033681 | 0.74 | CCR2 (0.52) | CCR2CCR5CYP2C19 | |
| SCHEMBL15033674 | 0.73 | CCR2 (0.53) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721025-B1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | CCR2 1/4885CCR3 7/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.